TWi Biotechnology Inc

TWi Biotechnology, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative therapeutics in dermatology and central nervous system (CNS) disorders through the US FDA's 505(b)(2) regulatory pathway. Our portfolio features 3 clinical-stage drug candidates targeting multiple indications, alongside a growing pipeline of projects under early-stage development. Based in Taipei, Taiwan, we operate with a global perspective, conducting international clinical studies and collaborating with world-class consultants and key opinion leaders. Our shares are publicly traded in Taiwan (ticker: 6610.TWO).